Post-prandial Glycemic Response to Fiber in Healthy Adults

Post-prandial Glucose and Insulin Response to High-fiber Muffin Top Containing Resistant Starch in Healthy Adults

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03252704

Enrollment

Registered

2017-08-17

Start date

2016-03-31

Completion date

2016-10-31

Last updated

2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucose, High Blood, Glucose, Low Blood, Meals

Keywords

postprandial glucose insulin

Brief summary

This randomized, double-blind, comparator controlled trial evaluated the blood glucose and insulin responses in healthy adults, after consuming a high fiber or low fiber muffin top.

Detailed description

The fiber administered in this trial is a resistant starch type 4 derived from high-amylose maize starch. This product is high in dietary fiber (70% total dietary fiber (TDF), AOAC 2009.01 method) and can be used in a variety of bakery applications. The objective of this study was to evaluate the post-prandial blood glucose and insulin responses of healthy adults (n=28) after consuming a muffin top made with resistant starch or control muffin top, in a randomized, double-blind, crossover study. The muffin tops were matched for total weight, total carbohydrate, sugars, protein, and fat. During each 24-hour study period, subjects consumed a standard evening meal, fasted for 12 hours, and arrived at the study clinic the following morning. Serum glucose, serum insulin, and capillary glucose were measured after muffin top consumption. The subjects completed a seven day washout between treatments.

Interventions

OTHERresistant starch (high fiber muffin top)

Muffin top contained 11 g of fiber per portion

OTHERcontrol (low fiber muffin top)

Muffin top contained 1 g of fiber per portion

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Masking description

Study products were concealed in opaque foil envelopes. The treatments were identified by alphanumeric code. The subjects and investigators did not know the identity of the treatments.

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* 18 years of age or older, * BMI 18.0-29.9 kg/m2, * fasting glucose ≤ 6.0 mmol/L; * if female, not of childbearing potential (e.g. taking oral contraceptives, past hysterectomy)

Exclusion criteria

* diagnosed metabolic or chronic diseases (e.g. type-2 diabetes); * cancer diagnosis or treatment within 5 years; * gastrointestinal problems; * bowel cleansing during prior week; * current medications to control blood glucose; * current medications to control blood cholesterol ; * current medications to control blood pressure; * smoker; * use of medical marijuana; * alcohol or drug abuse treatment in past 12 months; * allergy or sensitivity to study products; * blood donation in prior 2 months; * if female, currently pregnant, currently breastfeeding, or planning to become pregnant

Design outcomes

Primary

Measure	Time frame	Description
Blood glucose response	0-4 hours after consumption	IV and capillary

Secondary

Measure	Time frame	Description
Blood insulin response	0-4 hours after consumption	IV
Breath hydrogen response	0-24 hours after consumption	Expired air

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026